Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Hangzhou Tigermed Consulting Co., Ltd (3347.HK)

27.350
+0.150
+(0.55%)
At close: 4:08:32 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
6,507,059.456
6,603,120.163
7,384,039.461
7,085,471.469
5,213,538.054
Cost of Revenue
4,423,408.984
4,361,106.946
4,535,510.633
4,277,007.584
2,942,882.998
Gross Profit
2,083,650.472
2,242,013.217
2,848,528.828
2,808,463.885
2,270,655.056
Operating Expense
1,176,645.110
1,174,023.760
1,092,571.867
997,689.980
892,767.123
Operating Income
907,005.362
1,067,989.457
1,755,956.961
1,810,773.905
1,377,887.933
Net Non Operating Interest Income Expense
-109,757.328
-56,088.525
105,714.660
137,992.449
228,196.288
Pretax Income
445,722.647
664,461.508
2,488,533.058
2,585,377.424
3,684,565.815
Tax Provision
200,480.886
216,630.221
338,606.215
313,651.998
292,863.593
Net Income Common Stockholders
335,540.231
405,143.492
2,024,849.989
2,006,552.035
2,874,163.020
Basic EPS
0.39
--
2.34
2.32
3.31
Diluted EPS
0.39
--
2.34
2.32
3.30
Basic Average Shares
862,070.196
--
865,320.508
864,893.119
868,327.196
Diluted Average Shares
862,070.196
--
865,320.508
864,893.119
870,958.491
Total Operating Income as Reported
446,727.166
664,419.012
2,486,940.557
2,582,398.509
3,696,966.922
Total Expenses
5,600,054.094
5,535,130.705
5,628,082.500
5,274,697.564
3,835,650.121
Net Income from Continuing & Discontinued Operation
335,540.231
405,143.492
2,024,849.989
2,006,552.035
2,874,163.020
Normalized Income
673,991.483
763,797.026
1,779,074.476
1,557,764.950
1,226,040.632
Interest Income
--
90,219.276
229,848.680
227,338.326
255,876.556
Interest Expense
--
141,235.382
119,897.366
83,178.711
24,910.070
Net Interest Income
-109,757.328
-56,088.525
105,714.660
137,992.449
228,196.288
EBIT
644,712.795
805,696.890
2,608,430.424
2,668,556.135
3,709,475.885
EBITDA
644,712.795
1,129,837.130
2,914,115.876
2,933,301.417
3,898,398.835
Reconciled Cost of Revenue
4,423,408.984
4,361,106.946
4,535,510.633
4,277,007.584
2,942,882.998
Reconciled Depreciation
--
324,140.240
305,685.452
264,745.282
188,922.951
Net Income from Continuing Operation Net Minority Interest
335,540.231
405,143.492
2,024,849.989
2,006,552.035
2,874,163.020
Total Unusual Items Excluding Goodwill
-564,085.422
-532,145.643
284,484.326
510,750.104
1,790,432.949
Total Unusual Items
-564,085.422
-532,145.643
284,484.326
510,750.104
1,790,432.949
Normalized EBITDA
1,208,798.216
1,661,982.773
2,629,631.550
2,422,551.313
2,107,965.887
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-225,634.169
-173,492.109
38,708.813
61,963.019
142,310.560
12/31/2021 - 8/7/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

300685.SZ Amoy Diagnostics Co., Ltd.
21.20
+1.83%
 
603108.SS Shanghai Runda Medical Technology Co., Ltd.
18.99
+4.80%
 
300676.SZ BGI Genomics Co., Ltd.
49.43
+2.40%
 
603259.SS WuXi AppTec Co., Ltd.
60.34
+1.98%
 
2268.HK WuXi XDC Cayman Inc.
37.100
-4.26%
 
2359.HK WuXi AppTec Co., Ltd.
62.350
-3.18%
 
ILMN Illumina, Inc.
78.17
+0.37%